ProKidney Corp. (PROK)
NASDAQ: PROK · IEX Real-Time Price · USD
2.200
+0.050 (2.33%)
At close: May 3, 2024, 4:00 PM
2.190
-0.010 (-0.45%)
After-hours: May 3, 2024, 5:18 PM EDT
ProKidney Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
163
Market Cap
505.82M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPROK News
- 5 weeks ago - ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations - GlobeNewsWire
- 6 weeks ago - ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - ProKidney to Participate in Jefferies Biotech on the Bay Summit - GlobeNewsWire
- 5 months ago - ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer - GlobeNewsWire
- 5 months ago - ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference - GlobeNewsWire
- 6 months ago - ProKidney Reports Third Quarter Financial Results - GlobeNewsWire
- 6 months ago - ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023 - GlobeNewsWire